Sepsis is a global health priority, yet effective host-directed targeted therapies have not been identified outside of the setting of COVID-19. Lymphopenia occurs in up to ~52% of patients with… Click to show full abstract
Sepsis is a global health priority, yet effective host-directed targeted therapies have not been identified outside of the setting of COVID-19. Lymphopenia occurs in up to ~52% of patients with sepsis and is associated with a higher mortality at both 30 and 100 days. In COVID-19, the presence of lymphopenia correlates with intensive care unit (ICU) admission, acute respiratory distress syndrome (ARDS) and death. The mechanisms underpinning lymphopenic sepsis remain unknown, and while high rates of lymphocyte apoptosis have been implicated, the relative contributions of cellular trafficking to inflamed tissues and reduction in lymphopoiesis require investigation. Further delineation of these underlying mechanisms holds the potential to open new avenues for the development of host-directed therapies in lymphopenic sepsis. These may include recombinant cytokines (e.g. IL-7), monoclonal antibodies (e.g. anti-IL-1, anti-PD-1) and siRNA (e.g. targeting IL-10, TGFβ). Applying the frontier tools of translational cellular and genomic medicine to understand lymphopenia in the setting of critical infections holds the potential to significantly reduce the excessive global burden of sepsis.
               
Click one of the above tabs to view related content.